A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Panitumumab as second line treatment in patients with KRAS wild type unresectable advanced colorectal cancer (mCRC).

ABSTRACT: Interventions: Trial of irinotecan / TS-1 (IRIS) + Panitumumab as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) Primary outcome(s): RR Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2624715 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR